Works matching IS 14363291 AND DT 2022 AND VI 25 AND IP 1
Results: 29
Correction to: DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial–mesenchymal transition in gastric cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known?
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 1, doi. 10.1007/s10120-021-01260-y
- By:
- Publication type:
- Article
Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 245, doi. 10.1007/s10120-021-01244-y
- By:
- Publication type:
- Article
Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 170, doi. 10.1007/s10120-021-01243-z
- By:
- Publication type:
- Article
Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 138, doi. 10.1007/s10120-021-01242-0
- By:
- Publication type:
- Article
Nationwide cohort study: cholesterol level is inversely related with the risk of gastric cancer among postmenopausal women.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 11, doi. 10.1007/s10120-021-01241-1
- By:
- Publication type:
- Article
Correction to: Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Integrin β1 orchestrates the abnormal cell-matrix attachment and invasive behaviour of E-cadherin dysfunctional cells.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 124, doi. 10.1007/s10120-021-01239-9
- By:
- Publication type:
- Article
Risk factors and oncological impact of positive resection margins in gastrectomy for cancer: are they salvaged by an additional resection?
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 287, doi. 10.1007/s10120-021-01238-w
- By:
- Publication type:
- Article
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 235, doi. 10.1007/s10120-021-01237-x
- By:
- Publication type:
- Article
Insulin and the insulin receptor collaborate to promote human gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 107, doi. 10.1007/s10120-021-01236-y
- By:
- Publication type:
- Article
New response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 218, doi. 10.1007/s10120-021-01234-0
- By:
- Publication type:
- Article
Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 226, doi. 10.1007/s10120-021-01233-1
- By:
- Publication type:
- Article
Trends in clinical outcomes and long-term survival after robotic gastrectomy for gastric cancer: a single high-volume center experience of consecutive 2000 patients.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 275, doi. 10.1007/s10120-021-01231-3
- By:
- Publication type:
- Article
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 207, doi. 10.1007/s10120-021-01230-4
- By:
- Publication type:
- Article
Synergistic effects of Rapamycin and Fluorouracil to treat a gastric tumor in a PTEN conditional deletion mouse model.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 96, doi. 10.1007/s10120-021-01229-x
- By:
- Publication type:
- Article
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 197, doi. 10.1007/s10120-021-01227-z
- By:
- Publication type:
- Article
Genomic landscape of a mouse model of diffuse-type gastric adenocarcinoma.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 83, doi. 10.1007/s10120-021-01226-0
- By:
- Publication type:
- Article
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 22, doi. 10.1007/s10120-021-01225-1
- By:
- Publication type:
- Article
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 188, doi. 10.1007/s10120-021-01224-2
- By:
- Publication type:
- Article
Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 149, doi. 10.1007/s10120-021-01223-3
- By:
- Publication type:
- Article
Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 33, doi. 10.1007/s10120-021-01222-4
- By:
- Publication type:
- Article
CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 64, doi. 10.1007/s10120-021-01220-6
- By:
- Publication type:
- Article
Brain metastases in gastroesophageal cancers—an underestimated complication.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 161, doi. 10.1007/s10120-021-01219-z
- By:
- Publication type:
- Article
Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 180, doi. 10.1007/s10120-021-01218-0
- By:
- Publication type:
- Article
Development of a predictive model for extragastric recurrence after curative resection for early gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 255, doi. 10.1007/s10120-021-01217-1
- By:
- Publication type:
- Article
Remission of type 2 diabetes after gastrectomy for gastric cancer: diabetes prediction score.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 265, doi. 10.1007/s10120-021-01216-2
- By:
- Publication type:
- Article
Hypoxia associated lncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK14.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 44, doi. 10.1007/s10120-021-01213-5
- By:
- Publication type:
- Article